SCHEMBL5401326

SCHEMBL5401326

COc1ccc(CSC2CCN(S(C)(=O)=O)CC2COCc2ccccc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPT P10636 2/20 0.39
POLB P06746 1/20 0.39
LMNA P02545 2/20 0.39
RECQL P46063 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
PKM P14618 1/20 0.38
RORC P51449 2/20 0.38
CTSL P07711 1/20 0.38
CTSB P07858 1/20 0.38
CTSK P43235 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MMP1 P03956 1/20 0.38
MMP2 P08253 1/20 0.38
MMP3 P08254 1/20 0.38
MMP9 P14780 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5401424 0.86 ALDH1A1 (0.46) ALDH1A1NPSR1MEN1KMT2ALMNA
SCHEMBL5404130 0.86 ALDH1A1 (0.46) ALDH1A1NPSR1MEN1KMT2ALMNA
SCHEMBL5401429 0.86 ALDH1A1 (0.46) ALDH1A1NPSR1MEN1KMT2ALMNA
SCHEMBL5415425 0.83 ALDH1A1 (0.47) ALDH1A1MEN1KMT2AMAPTPOLB
SCHEMBL5409167 0.76 FABP6 (0.42) ALDH1A1MAPTPOLBRECQLRORC
SCHEMBL5415458 0.73 ALDH1A1 (0.48) ALDH1A1MEN1KMT2AMAPTPOLB
SCHEMBL5717246 0.70 ALDH1A1 (0.53) ALDH1A1POLBRECQLCTSLCTSB
SCHEMBL5421639 0.70 CTSL (0.38) ALDH1A1MEN1KMT2APOLBLMNA
SCHEMBL5407490 0.70 ALDH1A1 (0.40) ALDH1A1POLBLMNARECQLCTSL
SCHEMBL9414492 0.66 CHRM5 (0.43) SIGMAR1CHRM5CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7189756-B2 Pyrrolidine derivatives HOFFMAN-LA ROCHE INC. (US) 2007-03-13 US disclosed
US-20040242672-A1 Useful as inhibitors of metalloproteases, e.g. zinc proteases; effective in treating disease states associated with vasoconstriction such as high blood pressure, coronary disorders, cardiac insufficiency, renal and myocardial ischaemia, renal insufficiency, dialysis, cerebral ischaemia AEBI JOHANNES (CH) 2004-12-02 US disclosed
US-6790860-B2 USEFUL AS INHIBITORS OF METALLOPROTEASES, E.G. ZINC PROTEASES; EFFECTIVE IN TREATING DISEASE STATES ASSOCIATED WITH VASOCONSTRICTION HOFFMANN-LA ROCHE INC. 2004-09-14 US disclosed
US-20030199569-A1 Pyrrolidine derivatives AEBI JOHANNES (CH) 2003-10-23 US disclosed
EP-1303486-A1 PYRROLIDINE DERIVATIVES AS METALLOPROTEASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 EP disclosed
US-20020040146-A1 Pyrrolidine derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2002-04-04 US disclosed
WO-2002008185-A1 PYRROLIDINE DERIVATIVES AS METALLOPROTEASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2002-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199569-A1 Pyrrolidine derivatives PREP, PEPD, MMP3 ALDH1A1 1186/4885NPSR1 589/4885MEN1 3251/4885
US-20020040146-A1 Pyrrolidine derivatives PREP, PEPD, MMP3 ALDH1A1 1186/4885NPSR1 589/4885MEN1 3251/4885
US-20040242672-A1 Useful as inhibitors of metalloproteases, e.g. zinc proteases; effective in treating disease states associated with vasoconstriction such as high blood pressure, coronary disorders, cardiac insufficiency, renal and myocardial ischaemia, renal insufficiency, dialysis, cerebral ischaemia MMP1, PEPD, MMP25 ALDH1A1 2463/4885NPSR1 1506/4885MEN1 2874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.